Harmony Biosciences Holdings, Inc.

NasdaqGM HRMY

Harmony Biosciences Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 681.88 M

Harmony Biosciences Holdings, Inc. Revenue is USD 681.88 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 25.83% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Harmony Biosciences Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 541.92 M, a 35.22% change year over year.
Harmony Biosciences Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 400.76 M, a 48.15% change year over year.
Harmony Biosciences Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 270.51 M, a 147.16% change year over year.
Harmony Biosciences Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 109.45 M.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqGM: HRMY

Harmony Biosciences Holdings, Inc.

CEO	Dr. Jeffrey M. Dayno M.D.
IPO Date	Aug. 19, 2020
Location	United States
Headquarters	630 West Germantown Pike
Employees	246
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Key trends

Past 5 years